Navigation Links
TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction
Date:7/30/2009

ive items related to the merger as to be set forth in the S-4. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2008 and TorreyPines' other SEC reports. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and TorreyPines undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

    Company contact:
    Paul Schneider
    TorreyPines Therapeutics, Inc.
    858-623-5665 X125


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. TorreyPines Therapeutics Reports Third Quarter 2007 Results
7. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... YARDLEY , Pennsylvanie, 18 septembre 2014 ... Lyon en 1974, a été ... à compléter les évaluations cliniques traditionnelles par ... Reported Outcomes) et sur les impacts économiques ... http://photos.prnewswire.com/prnh/20140618/119365 A cours ...
(Date:9/18/2014)... can be pretty expensive. Now a team led by ... open-source library of designs that will let scientists slash ... the syringe pump. , Syringe pumps are used to ... or mixing chemicals in a reaction. They can also ... Pearce and his team of Michigan Tech students published ...
(Date:9/18/2014)... September 18, 2014 Silicon-valley Electronic Data ... Digitaliza TXT , the latest addition to Clinovo’s ... Clinical Research Organization (CRO) Program, Clinovo further expands its ... days of ClinCapture training, we are now able to ... Ana Pulido. “We can also rely on Clinovo to ...
(Date:9/17/2014)... FRANCISCO , Sept. 17, 2014 ... receiving accelerated partial breast irradiation (APBI) via interstitial ... those with positive lymph nodes could be suitable ... Radiation Oncology (ASTRO) guidelines place these patients in ... abstract at the 2014 ASTRO meeting, Beaumont Health ...
Breaking Biology Technology:1974 - 2014 - Mapi fête ses 40 ans 2Doing science just got cheaper -- and faster 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4
... Corporation,(Nasdaq: VOLC ) today announced that it will ... of fiscal 2007 on Tuesday, February 12., The ... financial,results and operating activities open to all interested parties ... Time), Tuesday, February,12, hosted by Scott Huennekens, president and ...
... Begin at ProHEALTH Facility by End of First Quarter, ... NBS ),which is pioneering the pre-disease collection, processing ... need, today announced,receipt of a provisional license for comprehensive ... from the New York State,Department of Health for the ...
... - Three New Board Members to Form Audit ... 5 /Xinhua-PRNewswire-FirstCall/ --,China Pharma Holdings, Inc. ("China Pharma") ... generic and brand,bio-pharmaceutical products in China, today announced ... Baowen Dong to its Board of Directors,forming the ...
Cached Biology Technology:Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast 2NeoStem Announces NY State License for Adult Stem Cell Collection 2NeoStem Announces NY State License for Adult Stem Cell Collection 3China Pharma Appoints Three Independent Non-Executive Directors 2China Pharma Appoints Three Independent Non-Executive Directors 3
(Date:9/18/2014)... up to 400 kilometres in search of a home, which ... Clownfish spend their entire adult lives under the protection of ... open ocean, says study co-author, Dr Hugo Harrison from the ... at James Cook University. , "In the past we haven,t ... rare glimpse into how far they can swim, crossing large ...
(Date:9/17/2014)... care to reproductive technologies, the justice and well-being ... people to identify key issues, articulate their values ... the most defensible ways forward. But what are ... conversations?, The Hastings Center and the Presidential Commission ... up to publish a series of essays to ...
(Date:9/17/2014)... the Arts and Humanities has received a $260,000 grant ... project, "The Boundaries of the Human in the Age ... a wide-ranging series of events aimed at exploring two ... artists and researchers who are exploring the boundaries of ... humanism, and the other involves the increasingly influential hypothesis ...
Breaking Biology News(10 mins):Nemo's epic journey to find a new home 2Why bioethics literacy matters 2Why bioethics literacy matters 3Mellon Foundation awards grant for major project in the humanities and sciences 2
... April 22, 2012) Researchers at Columbia University Medical ... the retention and release of the brain,s stem cells. ... neurologic development and could eventually lead to regenerative therapies ... collaborative effort of the laboratories of Drs. Anna Lasorella ...
... reductions in salt content and taxation on products containing salt ... each year from cardiovascular disease (CVD) by 2-3 per cent ... World Congress of Cardiology are the first findings from a ... year. The study set out to assess ...
... the Florida campus of The Scripps Research Institute has been ... Health to develop a range of new tests that could ... degenerative disorders of advancing age. Shuji Kishi, an assistant ... three-year study. The new tests will focus on diseases ...
Cached Biology News:'Housekeeping' mechanism for brain stem cells discovered 2'Housekeeping' mechanism for brain stem cells discovered 3Tax on salt could reduce cardiovascular disease deaths by 3 percent 2Researcher awarded $1 million for stress-associated disease and aging research 2
Rabbit polyclonal to Leucyl tRNA synthetase ( Abpromise for all tested applications). Antigen: L930-H1176 denatured human recombinant LRS. Entrez Gene ID: 3926 Swiss Protein ID: Q9P2J5...
Neutrophil cytosol factor 2 (NCF-2) (Neutrophil NADPH oxidase factor 2) (67 kDa neutrophil oxidase factor) (p67-phox) (NOXA2). [Source:Uniprot/SWISSPROT;Acc:P19878] Antigen: Recombinant Protein E...
... Rabbit polyclonal to FANCM ( Abpromise ... Antigen: Synthetic peptide derived from ... Human FANCM. (Note: the amino acid ... available as ab27787 .) ...
Rabbit polyclonal to 13,14 dihydro 15 keto Prostaglandin E2 ( Abpromise for all tested applications)....
Biology Products: